Skip Navigation

Europace 2007 9(1):31-33; doi:10.1093/europace/eul169
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brignole, M.
Right arrow Articles by Sutton, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brignole, M.
Right arrow Articles by Sutton, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


SYNCOPE

Pacing for neurally mediated syncope: is placebo powerless?

M. Brignole1,* and R. Sutton2

1 Department of Cardiology, Ospedali del Tigullio, Via don Bobbio, 16033 Lavagna, Italy; 2 Department of Cardiology, Royal Brompton and Harefield Hospitals, London, UK

Background After two recent controlled trials failed to prove superiority of cardiac pacing over placebo in patients affected by neurally mediated syncope, a widely accepted opinion is that cardiac pacing therapy is not very effective and that a strong placebo effect exists.

Aim To measure the effect of placebo pacing therapy.

Method and results We compared the recurrence rate of syncope during placebo vs. no treatment in controlled trials of drug or pacing therapy. Syncope recurred in 38% of 252 patients randomized to placebo pooled from five trials vs. 34% of 881 patients randomized to no treatment pooled from eight trials. The corresponding recurrence rate with active cardiac pacing was 15% in 203 patients from six trials.

Conclusions Placebo is not an effective therapy for neurally mediated syncope. Different selection criteria in patients who are candidates for cardiac pacing—for example, presence, absence, or severity of the cardioinhibitory reflex may separate positive from negative trials.

Key Words: Syncope, Neurally mediated syncope, Pacemaker therapy, Electrocardiographic monitoring, Implantable loop recorder


* Corresponding author. Tel: +39 0185 329569; fax: +39 0185 306506. E-mail address: mbrignole{at}asl4.liguria.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
QJMHome page
S.W. Parry, T. Chadwick, J.C. Gray, R.S. Bexton, M. Tynan, J.P. Bourke, and S. Nath
The intravenous adenosine test: a new test for the identification of bradycardia pacing indications? A pilot study in subjects with bradycardia pacing indications, vasovagal syncope and controls
QJM, July 1, 2009; 102(7): 461 - 468.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S W Parry, P Reeve, J Lawson, F E Shaw, J Davison, M Norton, R Frearson, S Kerr, and J L Newton
The Newcastle protocols 2008: an update on head-up tilt table testing and the management of vasovagal syncope and related disorders
Heart, March 1, 2009; 95(5): 416 - 420.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. P. Tan and S. W. Parry
Vasovagal syncope in the older patient.
J. Am. Coll. Cardiol., February 12, 2008; 51(6): 599 - 606.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.